CN102836247B - Tangerine extract composition for feminite care - Google Patents
Tangerine extract composition for feminite care Download PDFInfo
- Publication number
- CN102836247B CN102836247B CN201210337406.XA CN201210337406A CN102836247B CN 102836247 B CN102836247 B CN 102836247B CN 201210337406 A CN201210337406 A CN 201210337406A CN 102836247 B CN102836247 B CN 102836247B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- parts
- vitamin
- extract composition
- hesperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000000284 extract Substances 0.000 title abstract description 8
- 241000675108 Citrus tangerina Species 0.000 title abstract 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 22
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 13
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 13
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 13
- 229940025878 hesperidin Drugs 0.000 claims abstract description 13
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 13
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims abstract description 10
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 10
- 229930019673 naringin Natural products 0.000 claims abstract description 10
- 229940052490 naringin Drugs 0.000 claims abstract description 10
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001587 hesperetin Drugs 0.000 claims abstract description 9
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 9
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 9
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims abstract description 9
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 9
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 claims abstract description 9
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims description 19
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 claims description 9
- 108010084210 citrin Proteins 0.000 claims description 9
- 230000000694 effects Effects 0.000 abstract description 18
- 230000001954 sterilising effect Effects 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 3
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract description 2
- 244000045947 parasite Species 0.000 abstract description 2
- 230000003405 preventing effect Effects 0.000 abstract description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract 2
- 229910021529 ammonia Inorganic materials 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 11
- 239000007921 spray Substances 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 210000001215 vagina Anatomy 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 241001672694 Citrus reticulata Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 235000020971 citrus fruits Nutrition 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- -1 flavone compound Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 241000207199 Citrus Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940087305 limonene Drugs 0.000 description 3
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000305071 Enterobacterales Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010018275 Gingival atrophy Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a tangerine extract composition for feminite care, which is composed of the following components in parts by weight: 0.2 to 18 parts of hesperidin, 0.04 to 1.24 parts of neohesperidin, 0.015 to 0.86 parts of naringin, 0.01 to 0.5 parts of limonin, 0.05 to 2.5 parts of vitamin P, 0.03 to 0.85 parts of hesperetin and 0.25 to 13.8 parts of vitamin C. The tangerine extract composition for feminite care provided by the invention has the following technical effects: the synergy of the components is realized, the hesperidin, the neohesperidin, the naringin, the limonin, the vitamin P, the hesperetin and the vitamin C are jointly functioned on preventing the cell plasma membranes from absorbing an ammonia acid and blocking the cell respiration, so that the effect on damaging the microbial cell membranes is achieved, and the effect on effectively killing the harmful microorganisms including bacteria, fungi, viruses and parasites and the like is realized. The tangerine extract composition is a natural physical sterilizing product in a real sense.
Description
Technical field
The present invention relates to a kind of extraction of the Fructus Citri tangerinae for feminine care compositions, belong to medicines and health protection technical field.
Background technology
Fructus Citri tangerinae extraction (being Citrus reticulata Blanco extract) has the bactericidal activity history of this existing centuries of research, as " extraction of the Pericarpium Citri Reticulatae active component such as hesperidin and bacteriostasis research " (Ma Qingyi, Chen Chuntao, Jing Xiaoyan, Yuan Weixia) in research, point out that hesperidin is under acid condition, due to the ability all greatly reinforcement of hesperidin with sour its anti-bacteria of synergism and mycete.Hesperidin has not only strengthened the activity of anti-bacteria under acid is collaborative, has also produced strong anti-mildew effect." advances and application of flavone compound in Citrus " (Peng Yan, Sheng Xuefei, Wu Dan, Chen Jianchu) point out in Citrus the physiologically actives such as the main flavone compound existing and antioxidation thereof, anticancer, angiocardiopathy preventing, antiinflammatory, antiallergic, inhibition microorganism in research.The exploitation situation of Citrus flavone compounds at aspects such as food, medicine, animal feeds has been discussed simultaneously." peel of Citrus reticulata Blanco functional components present Research and development prospect " (closes Haining, Diao little Qin, Zhang Runguang) from essential oil, pectin, natural pigment, dietary fiber, flavone compound and six aspects of limonoid, summarized the present Research of functional activity composition in peel of Citrus reticulata Blanco, and its extremely valuable development prospect has been looked forward to." the bacteriostasis property research of natural activity monoterpene-limonene " (Wang Xuemei; Chen Hui; Li Xuejiao; Sun Yonghong; high glow) work out limonene escherichia coli, bacillus subtilis, bacillus thuringiensis, beer yeast, bakery yeast and aspergillus niger are all had to good inhibition; especially better to beer yeast and bakery yeast inhibition, there is broad spectrum antibacterial; Also point out that in addition limonene, as natural antiseptic agent, has good application prospect.
Fructus Citri tangerinae extraction is nontoxic organic sterilising prods.It demonstrates the inhibitory action to bacterial growth when test tube is tested, and can also suppress some viral infection ability simultaneously.Therefore this extract by extensively as disinfection solvent composition, food or cosmetics preservative and industrial as antifungal, antibacterial, except parasitic agent and anti-filterability toadstool agent are used.In Italy, Fructus Citri tangerinae extraction has been also one of Traditional Folk prescription since 16th century, is used to treatment and resembles the calentura such as malaria and use as antibacterial.
Make a general survey of the research of above-mentioned Fructus Citri tangerinae extraction (Citrus reticulata Blanco extract), all pointed out even other drug effect of its good sterilization having, antioxidation, anti-corrosive fresh-keeping, but also do not occur Fructus Citri tangerinae to extract the product that carries out industrialization production.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art part, a kind of extraction of the Fructus Citri tangerinae for feminine care compositions is provided.
Fructus Citri tangerinae for feminine care extraction compositions of the present invention, said compositions is composed of the following components:
| Component | Component ratio |
| Hesperidin | 0.2-18 weight portion |
| Neohesperidin | 0.04-1.24 weight portion |
| Naringin | 0.015-0.86 weight portion |
| Limonin | 0.01-0.5 weight portion |
| Citrin | 0.05-2.5 weight portion |
| Hesperetin | 0.03-0.85 weight portion |
| Vitamin C | 0.25-13.8 weight portion |
Preferably,
The described extraction of the Fructus Citri tangerinae for feminine care compositions, said compositions is composed of the following components
| Component | Component ratio |
| Hesperidin | 8-12 weight portion |
| Neohesperidin | 0.076-1.02 weight portion |
| Naringin | 0.03-0.26 weight portion |
| Limonin | 0.016-0.13 weight portion |
| Citrin | 0.08-0.15 weight portion |
| Hesperetin | 0.06-0.33 weight portion |
| Vitamin C | 5.2-8.24 weight portion |
Fructus Citri tangerinae for feminine care extraction compositions of the present invention, its preparation method is as follows: citrus fruit raw material presses pulverizing broken, add the cohobation of water post-heating, collect effect fraction, after mixing, all the other residues and mother solution store at 0 ℃ to 10 ℃, collect after layering supernatant and with collect before fraction and mix, adjusting PH to 3.2-5.0.
Fructus Citri tangerinae for feminine care extraction compositions of the present invention,
Hesperidin proportion is 0.2-18 weight portion, 8-12 weight portion preferably, and within the scope of this, hesperidin can be brought into play antiinflammatory antiviral, strengthen the effect of vitamin C effect:
Neohesperidin proportion is 0.04-1.24 weight portion, 0.076-1.02 weight portion preferably, and within the scope of this, under Citrin is assisted, performance maintains capillary permeability to neohesperidin, anticancer effect sterilizes:
Naringin proportion is 0.015-0.86 weight portion, 0.03-0.26 weight portion preferably, and within the scope of this, naringin can be brought into play the effect of antimicrobial antiphlogistic, antiviral, anti-peroxidation:
Limonin proportion is 0.01-0.5 weight portion, 0.016-0.13 weight portion preferably, and within the scope of this, limonin can strengthen naringin performance and suppress tumor, anticancer effect:
Citrin proportion is 0.05-2.5 weight portion, 0.08-0.15 weight portion preferably, and within the scope of this, Citrin can bring into play and prevent that vitamin C is oxidized, strengthen capillary permeability, prevent the effect of injury with blood-stasis:
Hesperetin proportion is 0.03-0.85 weight portion, 0.06-0.33 weight portion preferably, and within the scope of this, hesperetin can be brought into play the mediation of inflammatory mediator, the effect of removing peroxynitrite of suppressing:
Vitamin C proportion is 0.25-13.8 part, 5.2-8.24 part preferably, and within the scope of this, vitamin C and Citrin be collaborative can strengthen that performance Vitamin C is sick, promotion collagen protein synthesis, prevent gingival atrophy and hemorrhage, antioxidative effect:
Fructus Citri tangerinae for feminine care extraction compositions of the present invention has following technique effect: each composition has synergism, hesperidin, neohesperidin, naringin, limonin, Citrin, hesperetin and vitamin C combined effect stop cellular plasm film to absorb aminoacid, blocking-up Cellular respiration, thereby reach the effect of destroy microorganisms cell membrane, playing the harmful microbe effects such as effective kill bacteria, fungus, virus and parasite, is pure natural physical sterilization product truly.
The specific embodiment
embodiment 1-6 is for the Fructus Citri tangerinae extraction compositions of feminine care
The extraction of the Fructus Citri tangerinae for the feminine care compositions of embodiment 1-6, composed of the following components, its component and each component ratio are as shown in table 1:
Table 1:
embodiment 7 is for spray type feminine care liquid and the effect detection thereof of the Fructus Citri tangerinae extraction compositions of feminine care
The component of spray type feminine care liquid: Fructus Citri tangerinae extraction compositions accounts for (0.01-0.015) % of spray type feminine care liquid weight, and surplus is water.
Spray type feminine care liquid is carried out to toxicity detection (comprising acute eye irritation test and a vaginal mucomembranous irritant test) and bactericidal effect detection.
1, acute eye irritation test
1) material and animal
The spray type feminine care liquid of take is tested material.
Healthy without 3 of ophthalmic New Zealand white rabbit, regular grade, kind warren, Nanjing provides, quality certification SCXK(Soviet Union) No. 2007-0004, body weight 2.4-2.7kg, female 2, male 1.Animal feed source and card number: Jiangsu Province collaborative medical bioengineering company limited, the A of Soviet Union raises new word (2002) No. 009.
Experimental condition: regular grade laboratory animal environment, occupancy permit number: SYXK(Soviet Union) No. 2007-0020; Ambient temperature: 22 ± 2 ℃, relative humidity 40-70%; Before test, animal is quarantined and adapts to 3d in feeding environment.Key instrument: baby scale (numbering 05-713).
2) method
Test basis Ministry of Public Health (version in 2002) < < disinfection technology standard > > second portion 2.3.4 acute eye irritation test.
The method of inspection is as follows: get tested material 0.1ml and directly splash in rabbit one branch hole conjunctival sac, passive closed eyelid 4s, after 30s, with normal saline flushing, another eye drips with normal saline in contrast, 1h, 24h, 48h, 4d and 7d observed and recorded eye irritant reaction after eye drip.
3) result of the test
4) conclusion
The spray type feminine care liquid of the present embodiment belongs to nonirritant to the disposable eye of rabbit stimulus intensity.
2, a vaginal mucomembranous irritant test
1) material and animal
The spray type feminine care liquid of take is tested material.
Healthy without 6 of skin disease New Zealand white rabbit, regular grade, kind warren, Nanjing provides, quality certification SCXK(Soviet Union) No. 2007-0004, body weight 2.0-2.4kg.Animal feed source and card number: Jiangsu Province collaborative medical bioengineering company limited, the A of Soviet Union raises new word (2002) No. 009.
Experimental condition: regular grade laboratory animal environment, occupancy permit number: SYXK(Soviet Union) No. 2007-0020; Ambient temperature: 22 ± 2 ℃, relative humidity 40-70%; Before test, animal is quarantined and adapts to 3d in feeding environment.Aquesterilisa is freely drunk.Key instrument: baby scale (numbering 05-324).
2) method
Test basis Ministry of Public Health (version in 2002) < < disinfection technology standard > > second portion 2.3.5 vaginal mucomembranous irritant test.
The method of inspection is as follows: animal is divided into test group, matched group, 3 every group.Animal faces upward fixing, exposes perineum and vaginal orifice.The trumpet catheter of sterilizing is connected with 2ml syringe, after conduit is moistening by tested material, gently inserts (4-5cm) in animal vagina, and slowly inject 2ml tested material with disinfector, extract conduit out, complete contamination.Control animals is done same processing with normal saline.After 24h, adopt aeroembolism method to put to death animal, cut open the belly and take out complete vagina, longitudinally cut, perusal has or not the performances such as hyperemia, edema, reference during for pathologic sampling.Vagina is put into 10% formalin fixedly more than 24h, choose the tissue slice at three positions in two ends and central authorities of vagina, after HE dyeing, carry out histopathological examination.
3) result of the test
Perusal has no the hyperemia of control animals vaginal mucosa and edema, No. 2 animal vagina Mild edema of test group.Pathological study the results are shown in following table:
4) conclusion
The spray type feminine care liquid of the present embodiment is 0.78 to rabbit vagina mucous membrane irritation index, and vaginal mucosa stimulus intensity is nonirritant.
3, sterilization (Candida albicans, escherichia coli, staphylococcus aureus) effect detection
1) material and animal
The spray type feminine care liquid of take is tested material.
2) method
According to the disposable use hygienic article of < < sanitary standard > > (GB15979-2002).
Test organisms 24h slant culture is washed down with PBS, and (concentration of requirement is: with 100uL, drip in 5mL control sample liquid, bacterial count recovered is 1*10 to make bacteria suspension
4-9*10
4cfu/mL).
Get by each 4 pipe of test liquid (5mL) and control sample liquid (with sample homogeneous material, size on an equal basis, but containing anti-biotic material, and through sterilization treatment).
Get above-mentioned bacteria suspension, at each, drip 100uL in by test liquid and control sample liquid respectively, evenly mix, start timing, effect 2, 5, 10, 20min, with aseptic tweezer, respectively sample liquid (0.5mL) is dropped into containing 5mL PBS in vitro, fully mix, do suitably dilution, then get wherein 2-3 dilution factor, draw respectively 0.5mL, be placed in two plates, with cool nutrient agar (large enterobacteria and staphylococcus aureus) or sabouraud's agar (Candida albicans) 15mL to 40-45 ℃, pour into, rotate plate, make it full and uniform, it is dull and stereotyped that agar solidifies rear upset, cultivate the large enterobacteria of 48h(and staphylococcus aureus for 35 ℃ ± 2 ℃) or 72h(Candida albicans), do viable bacteria colony counting.
Test repeats 3 times, presses formula below and calculates bacteriostasis rate:
X?=?(?A-B?)?/?A?*?100?%
In formula: X---bacteriostasis rate, %;
A---the average clump count of control sample;
B---tested sample average clump count.
3) result of the test is as following table
| Test item | Standard value | Result |
| Candida albicans bacteriostasis rate (%) | ≥50 | 100 |
| Staphylococcus aureus bacteriostasis rate (%) | ≥50 | 100 |
| Escherichia coli bacteriostasis rate (%) | ≥50 | 100 |
4) conclusion: spray type feminine care liquid of the present invention is 100% to Candida albicans bacteriostasis rate, staphylococcus aureus bacteriostasis rate, escherichia coli bacteriostasis rate, and product has stronger bacteriostasis.
Claims (2)
1. for a Fructus Citri tangerinae extraction compositions for feminine care, it is characterized in that, said compositions consists of the following composition:
。
2. the extraction of the Fructus Citri tangerinae for feminine care compositions according to claim 1, is characterized in that, consists of the following composition:
。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210337406.XA CN102836247B (en) | 2012-09-13 | 2012-09-13 | Tangerine extract composition for feminite care |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210337406.XA CN102836247B (en) | 2012-09-13 | 2012-09-13 | Tangerine extract composition for feminite care |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102836247A CN102836247A (en) | 2012-12-26 |
| CN102836247B true CN102836247B (en) | 2014-03-05 |
Family
ID=47364150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210337406.XA Active CN102836247B (en) | 2012-09-13 | 2012-09-13 | Tangerine extract composition for feminite care |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102836247B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511557A (en) * | 2016-11-18 | 2017-03-22 | 苏州丽舒雅生物科技有限公司 | Orange extract-containing natural female nursing liquid and preparation method thereof |
| CN106511114A (en) * | 2016-11-18 | 2017-03-22 | 苏州丽舒雅生物科技有限公司 | Broad spectrum bactericidal pure natural orange extract essence and preparation method thereof |
| TWI731244B (en) * | 2018-05-31 | 2021-06-21 | 張仁維 | A composition containing a rutaceae plant extract |
-
2012
- 2012-09-13 CN CN201210337406.XA patent/CN102836247B/en active Active
Non-Patent Citations (10)
| Title |
|---|
| 刘学仁等.橙皮苷和橙皮素生物活性的研究进展.《中国新药杂志》.2011,第20卷(第04期), |
| 叶兴乾等.柑橘属类黄酮及其生理活性.《中国食品学报》.2008,(第05期), |
| 张向宇等.橘皮提取物对口腔常见致病菌的抑菌效果.《中国消毒学杂志》.2007,第24卷(第03期), |
| 柑橘属类黄酮及其生理活性;叶兴乾等;《中国食品学报》;20081030(第05期);1-5 * |
| 柑橘类果汁中柠檬苦素的含量及其性质研究;罗水忠等;《食品研究与开发》;20081205;第29卷(第12期);4 * |
| 橘皮提取物对口腔常见致病菌的抑菌效果;张向宇等;《中国消毒学杂志》;20070515;第24卷(第03期);248-249 * |
| 橙皮苷和橙皮素生物活性的研究进展;刘学仁等;《中国新药杂志》;2011;第20卷(第04期);329-333,381 * |
| 正交实验法优化枳壳提取工艺的研究;王玉金等;《中国医药指南》;201111;第9卷(第32期);55-56 * |
| 王玉金等.正交实验法优化枳壳提取工艺的研究.《中国医药指南》.2011,第9卷(第32期), |
| 罗水忠等.柑橘类果汁中柠檬苦素的含量及其性质研究.《食品研究与开发》.2008,第29卷(第12期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102836247A (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| CN102860923B (en) | Nano-silver antibacterial liquid soap and preparation method thereof | |
| CN104082353A (en) | Pure traditional Chinese medicine disinfectant and preparation method thereof | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN103410046B (en) | A kind of antimicrobial toilet paper manufacture method | |
| CN102470117A (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof | |
| CN103451032A (en) | Safe and environment-friendly tea seed washing powder and preparation method thereof | |
| CN108042578A (en) | A kind of health care vaginal jellies containing compound probiotic ingredient | |
| CN107836466A (en) | A kind of tea tree ethereal oil natural disinfectant agent for animals and preparation method thereof | |
| CN101543658B (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| CN106563129B (en) | It is a kind of for wound protection composition and its formation application | |
| CN102836247B (en) | Tangerine extract composition for feminite care | |
| CN113995744B (en) | Composition and antibacterial application thereof | |
| CN111493097A (en) | Collective disinfectant for inhibiting viruses and pathogenic bacteria and preparation method thereof | |
| CN106511114A (en) | Broad spectrum bactericidal pure natural orange extract essence and preparation method thereof | |
| CN106176603A (en) | A kind of plants essential oil micro emulsion gel and its preparation method and application | |
| CN107519248A (en) | A kind of mastadenitis of cow Chinese medicinal perfusion liquid and its preparation application method | |
| CN102038744B (en) | High-permeability environment-friendly high-efficiency skin disinfectant and preparation method thereof | |
| CN106267329A (en) | A kind of plants essential oil gel dressing and its preparation method and application | |
| CN101804094B (en) | Medicament for killing sperms in vitro | |
| CN106860491B (en) | Plant extracts and its production and use | |
| CN115590934A (en) | Gynecological lotion and preparation method and application thereof | |
| CN108324648A (en) | A kind of composition of anti-acne | |
| Dahikar et al. | Pharmacokinetics of Withania somnifera (Ashwagandha) in healthy buffalo calves. | |
| CN1977849A (en) | Kibe ointment with bactericidal-bacteriostasis function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU LISHUYA BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SUZHOU YIJIE BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141023 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20141023 Address after: Kwun Tong Road Xiangcheng Economic Development Zone, Suzhou City, Jiangsu Province, No. 1 215000 Patentee after: Suzhou Li Li Ya Biological Technology Co., Ltd. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215000 Xinghu Street No. 218 BioBAY building A2 room 227 Patentee before: Suzhou Yijie Biological Technology Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Kwun Tong Road Xiangcheng Economic Development Zone, Suzhou City, Jiangsu Province, No. 1 215000 Patentee after: Dr. orange Biotechnology (Suzhou) Co., Ltd. Address before: Kwun Tong Road Xiangcheng Economic Development Zone, Suzhou City, Jiangsu Province, No. 1 215000 Patentee before: Suzhou Li Li Ya Biological Technology Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wen Zhiling Inventor before: Lou Zhiqiang |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200213 Address after: 610000 No.3, floor 19, unit 1, building 1, No.199, middle section of Tianfu Avenue, Chengdu high tech Zone, China (Sichuan) pilot Free Trade Zone, Chengdu Patentee after: Chengdu Yixiang Biotechnology Co., Ltd Address before: 215000 No. 1, Kwun Tong Road, Xiangcheng Economic Development Zone, Jiangsu, Suzhou Patentee before: Dr. orange Biotechnology (Suzhou) Co., Ltd. |
|
| TR01 | Transfer of patent right |